🔗 Share this article

While the United States continues making sweeping adjustments to its immunization recommendations, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by casting doubt on COVID-19 shots during the pandemic and has focused upon possible deaths following COVID-19 immunization in her brief time at the FDA.

Proposed Changes to Childhood Vaccine Schedule

Health officials planned to unveil radical changes to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish immunization schedule, sources say – a significant shift that would place the US out of step with many the global community with little proof for public health gain. This reveal has been delayed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is set to address the audience at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to lead the center this year.

A New Direction at the Regulatory Body

The acting appointment might represent a strengthened alliance between the drug and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a greater focus upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for halting some childhood immunization guidelines in the US in order to be more similar to Denmark's approach, a society with universal health coverage and a citizenry approximately the size of Wisconsin’s.

To date statements, she has persisted in emphasizing on immunizations – typically the responsibility of Prasad, chief of the FDA’s vaccine center – instead of pharmaceutical oversight.

Concerns Over Expertise

Høeg has no apparent experience in drug development, approval processes or administrative roles, which has been typical for past directors of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and CBER since spring.

“It seems she lacks to have any of the qualifications” for running the CDER, remarked Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a large organization. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she doesn’t have the kind of background that former directors who led CBER have had.”

This division has an immense range of responsibilities at the FDA, the former commissioner stated.

“Many people just pays attention on the novel medication approvals, but the generic drug division approves thousands of generic medications. There is also a biosimilars program, over-the-counter program and more, and every single one have to be looked after,” Dr. Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major management aspect to the position, which oversees in excess of 5,000 personnel. “It’s a massive leadership role, if you perform it correctly,” the former official said.

Response and Disputed Programs

Regarding inquiries about Høeg’s qualifications and whether this appointment represents greater collaboration among agency officials on immunizations, a representative said that the “concerns are based on inaccurate assumptions”.

“This background aligns with the functions of her role,” the official explained, pointing to the period Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a contentious rapid drug-approval program that reportedly worried her predecessors. “By what process are these medications being selected for this voucher program? Who takes the calls?” Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

In general, he said, “the agency looks to be trending towards more relaxed oversight of most medications, with the exception of vaccines.”

Established Past Work on Vaccines

With immunizations, Høeg has a clearer, if problematic, past, critics observe. She published a analysis using non-validated volunteer-provided data to assess the incidence of myocarditis after COVID-19 immunization. She advised the state of Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are riskier than they are.

Among her “policy goals” for the new government included revising regulations for novel immunizations and halting “optional” vaccines, she said post-election on a online show. At the agency, Dr. Høeg has allegedly floated the idea of barring teenage boys from receiving Covid vaccines.

“She is an complete true believer who begins with her beliefs and works backwards to fit the evidence in a very misleading, untruthful manner,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg joined fellow skeptics, {like|